This company has been acquired
NewBridge Global Ventures Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on NewBridge Global Ventures's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2019 |
Recent past performance updates
No updates
Recent updates
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, NewBridge Global Ventures has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses BreakdownBeta
How NewBridge Global Ventures makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 19 | 0 | -10 | 9 | 0 |
| 31 Mar 19 | 0 | -5 | 5 | 0 |
| 31 Dec 18 | 0 | -3 | 4 | 0 |
| 30 Sep 18 | 0 | -2 | 3 | 0 |
| 30 Jun 18 | 0 | 0 | 0 | 0 |
| 31 Mar 18 | 0 | 0 | 0 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
| 31 Dec 16 | 0 | 0 | 0 | 0 |
Quality Earnings: Insufficient data to determine if NBGV has high quality earnings.
Growing Profit Margin: Insufficient data to determine if NBGV's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NBGV's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare NBGV's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if NBGV's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: NBGV has a negative Return on Equity (0%), as it is currently unprofitable.